Loading clinical trials...
Loading clinical trials...
To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in th...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Boehringer Ingelheim
NCT06087926 · Parkinson Disease
NCT07642908 · Parkinson Disease
NCT06680830 · Parkinson Disease, Parkinson, and more
NCT05822388 · Parkinson Disease, Movement Disorders
NCT06965374 · Parkinson Disease
Pivotal Reaserch Centers
Peoria, Arizona
Boehringer Ingelheim Investigational Site
Tucson, Arizona
PMDI
Fountain Valley, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions